Ayala focuses on treatment methods for metastatic adenoid cystic carcinoma patients, enabling therapy for cancers affecting the salivary glands.
Ayala is a clinical-stage oncology company founded in November 2017 after acquiring an exclusive, worldwide license to our product candidates AL101 and AL102 from Bristol-Myers Squibb (BMS). The firm is focused on developing and commercializing small molecule therapeutics for patients living with rare and aggressive cancers, especially in genetically defined patient populations. Ayala’s development approach is rooted in identifying and addressing indications in which Notch-pathway activation is known to be a tumorigenic driver. The firm uses a combination of next-generation sequencing and their bioinformatics platform to help develop Notch-targeted therapies to underserved patient populations. Advances in molecular testing and sequencing have enabled the discovery of Notch-activating mutations in multiple tumor types – providing them with additional tools to identify patients who are most likely to respond to the gamma secretase inhibitors Ayala develops.
Arc investment: 2018
Ayala Pharmaceuticals (AYLA) has filed a preliminary prospectus for a $50M IPO.The Rehovet, Israel-based biopharmaceutical outfit develops treatments for rare and aggressive cancers by leveraging its